We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

FDA Clears Hand-Held Test for Bordetella Pertussis

By LabMedica International staff writers
Posted on 04 Jan 2015
Quidel\'s AmpliVue Bordetella Assay
The AmpliVue Bordetella Assay (Photo courtesy of QuidelOrtho)
The United States Food and Drug Administration (FDA) have cleared an accurate, easy-to-use molecular diagnostic assay for Bordetella Pertussis that employs a unique hand-held platform and requires no pre-extraction of DNA.

The incidence of whooping cough, the very contagious disease caused by B. pertussis attaching to cilia that line part of the upper respiratory tract, has risen over the last few years. Whooping cough can cause serious illness in children and adults, and is most dangerous for infants and babies. Quidel Corporation (San Diego, CA, USA), a developer and provider of new diagnostic solutions, has received the FDA clearance for its AmpliVue Bordetella Assay to detect B. pertussis nucleic acids isolated from nasopharyngeal swab specimens obtained from patients suspected of having a respiratory tract infection attributable to B. pertussis.

AmpliVue Bordetella is an easy-to-use, self-contained, disposable molecular diagnostic test with superb clinical accuracy. The assay requires no upfront extraction of DNA and generates the result in approximately 75 minutes. The AmpliVue platform is based on Quidel’s novel Helicase Dependent Amplification (HDA) technology that enables rapid nucleic acid amplification without a thermal cycler. So, like all FDA-cleared AmpliVue assays, AmpliVue Bordetella is CLIA-classified as moderately complex and does not require investment in expensive thermocycling equipment. This benefit, plus less laboratory space requirements, can significantly lower cost when adopting new molecular testing methods.

"We are pleased to receive 510(k) clearance for our AmpliVue Bordetella Assay—our 5th assay in the AmpliVue format. We've shown that we can harness our proprietary HDA technology to develop fast, accurate molecular diagnostic assays with a menu that matters to our customers," said Douglas Bryant, president and CEO of Quidel, "Longer-term, we intend to leverage this technology for other molecular diagnostic applications that will be appealing to significant market segments and potentially to public health agencies worldwide."

Quidel's novel AmpliVue platform now enables laboratories of all sizes to perform highly sensitive and specific molecular tests, and currently has FDA clearance for B. Pertussis, C. difficile, Group A Strep, Group B Strep, HSV1 and HSV2.

Related Links:

Quidel Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more